KZIANasdaqPharmaceutical PreparationsFiscal year ends June 30
KAZIA THERAPEUTICS LTD
Financials through fiscal 2025, year ended Jun 30, 2025Last filing: 20-F on Nov 7, 2025
$7.85+0.60 (+8.28%)
Close on Oct 19, 2026
Share price
+$0.85 (+12.14%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
KAZIA THERAPEUTICS LTD saw revenue fall 98.2% to A$42.00K over fiscal 2025.
Revenue
A$42.00K
-98.2% vs. a year earlier
EPS, diluted
-0.04 AUD
FY2025
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- A$42.00K
- Net income
- -A$20.70M
- EPS, diluted
- -0.04 AUD
Valuation needs the share price. It fills in once daily prices are connected and converted from AUD.
Eleven years at a glance
Fiscal years 2015 to 2025, AUD
Revenue
A$42.00K-98.2% YoY
Net income
-A$20.70M
EPS, diluted
-0.04 AUD
Free cash flow
–
Reported period